A native of Australia, Dr. Moyle received his doctor of medicine from the University of Adelaide. Dr. Moyle has spent the last 12 years working in HIV research, mostly at the Chelsea and Westminster Hospital, northern Europe's largest HIV treatment centre, where he directs the phase 2-4 research program with a particular interest in toxicity prevention and management.
Dr. Moyle is an expert in HIV-related metabolic complications and toxicities of antiretrovirals and has published extensively on these subjects. He is the author of more than 100 major journal articles, as well as several chapters in HIV text books. He is on the editorial board of several HIV-related journals and an adviser to several UK-based PWA education organizations.
Dr. Moyle has been a consultant for Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck & Co., Tobira Therapeutics, Panacos Pharmaceuticals, Pfizer, Inc. and Tibotec. He has served on speakers bureaus for Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Pfizer and Tibotec. He has also received research support from Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Pfizer, Merck, Tibotec, Ardea Biosciences and Abbott Laboratories. In addition, he is the recipient of intellectual property rights from Merck Serono.